• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LIXTE Joins Russell Microcap Index

    6/26/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email

    BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its inclusion in the Russell Microcap® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026.

    "LIXTE’s inclusion in the Russell Microcap Index represents an important milestone for the Company and reflects the significant progress we have made over the past year," said Geordan Pursglove, Chief Executive Officer of LIXTE. "Under our new leadership team and strategic direction, we have successfully transformed the Company and enhanced shareholder value. We believe membership in the Russell Microcap Index will increase our visibility among institutional investors, broaden awareness of our growth strategy, and support our efforts to build a leading platform focused on AI energy infrastructure equipment and services. This recognition comes at a pivotal time as demand for power and infrastructure solutions continues to accelerate alongside the expansion of AI and hyperscale data centers."

    The Russell U.S. Indexes are among the most widely recognized benchmarks for institutional investors and investment managers. Membership in the Russell Microcap Index provides exposure to investment products and funds that benchmark their performance against Russell indexes.

    The Russell Microcap Index measures the performance of smaller publicly traded U.S. companies and serves as a widely followed benchmark for active and passive microcap investment strategies. Russell indexes are reconstituted annually to reflect changes in the U.S. equity market and to ensure that growing companies are appropriately represented.

    About LIXTE

    LIXTE Biotechnology Holdings, Inc. is a holding company that historically focused on the development of innovative cancer therapies and medical technologies. The Company is currently executing a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the rapidly growing power and infrastructure requirements of artificial intelligence, cloud computing, and hyperscale data center operators. Through this transition, LIXTE aims to capitalize on the accelerating demand for reliable, scalable, and efficient energy infrastructure solutions driven by the global expansion of AI.

    For more information about LIXTE, info@lixte.com, contact: 



    General Phone: (631) 830-7092; Investor Phone: (888) 289-5533

    or

    PondelWilkinson Inc. Investor Relations, pwinvestor@pondel.com

    Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962



    Primary Logo

    Get the next $LIXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Lixte Biotechnology Holdings Inc.

    PRE 14A - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)

    7/17/26 5:29:27 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)

    7/10/26 11:43:15 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    7/2/26 4:00:46 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

    Issued on behalf of NOMAD Power Solutions, Inc. (NASDAQ:NMAD), formerly LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT)NOMAD Power Solutions, Inc. has completed its corporate name change from LIXTE Biotechnology Holdings, Inc. and begins trading today under the new Nasdaq ticker NMAD, marking its transition into the AI energy infrastructure equipment and services sector following its acquisition of NOMAD Transportable Power SystemsAmerican News Group News CommentaryBOCA RATON, Fla., July 6, 2026 /CNW/ -- The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding power faster than the grid can add it through traditional fixed inf

    7/6/26 11:40:00 AM ET
    $FLNC
    $BE
    $GEV
    Industrial Machinery/Components
    Miscellaneous
    Energy
    Biotechnology: Pharmaceutical Preparations

    LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

     -- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company"), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) to NOMAD Power Solutions, Inc (NASDAQ:NMAD). The Company’s common stock will begin trading today under its new ticker, NMAD on the Nasdaq Stock Market. Shares under the symbol LIXT ceased trading at the close of market on Thursday, July 2, 2026. The new corporate name reflects the next chapter for the

    7/6/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

    -Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems-                                          -Company Plans Corporate Name Change to NOMAD Power Solutions                                       BOCA RATON, Fla./WATERBURY, Vt., July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc. ("NOMAD"), a market leader in deployable, utility-grade battery energy storage systems (BESS), In connection with the merger, the Company is issuing to the

    7/2/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Stazzone Peter was granted 50,000 shares, increasing direct ownership by 100% to 100,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:18:44 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sawyer Jason David was granted 40,000 shares, increasing direct ownership by 160% to 65,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:16:48 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Pursglove Geordan Garrett was granted 350,000 shares, increasing direct ownership by 100% to 700,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:13:51 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

    4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:39:03 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:36:30 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/4/23 6:10:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

    SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:59:12 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    3/3/21 7:45:27 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

    Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure BOCA RATON, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its strategic transformation into an AI energy infrastructure equipment & services platform focused on meeting the rapidly growing power demands of AI and hyperscale data centers. In connection with this transformation, Stuart D. Porter, Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital Managemen

    6/1/26 8:50:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

    -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

    9/3/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov. "2025 was a transformative and highly productive year for our Company," said Geordan Pursglove, who was named LIXTE's Chairman and Chief Executive Officer in June 2025. "We strengthened LIXTE's foundation by assembling an

    3/31/26 3:45:00 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care